Zobrazeno 1 - 10
of 15
pro vyhledávání: ''
Autor:
Kelsey Maguire, Andriy Derkach, Nandini Umesh Yadav, Jeffrey S. Groeger, Petros Grivas, Ali Raza Khaki, Adam Klotz, Margaret M. Madeleine, Esther Babady, Lisa Tachiki, Sandy Simcha Nath, Afia Babar, Gary H. Lyman, Ying Taur, Justin Jee, Sanjay Chawla, Molly Maloy, Rocio Perez-Johnston, Daniel J. Henning, H. Laura Aaltonen
Publikováno v:
Cancer investigation. 40(1)
Our goal was to identify discrete clinical characteristics associated with safe discharge from an emergency department/urgent care for patients with a history of cancer and concurrent COVID-19 infection during the SARS-CoV-2 pandemic and prior to wid
Publikováno v:
Cancer investigation. 40(3)
BACKGROUND Pain is a common symptom in cancer patients. Hypnosis is considered one of the most recognized non-pharmacological techniques in pain management. In oncology, this technique can be used as a complementary treatment to reduce the level of p
Autor:
Patrick Murphy, Lowell L. Hart, Adil Moyhuddin, Jeffrey Patton, Dana S. Thompson, Suzanne F. Jones, Chris Earwood, Jeffrey R. Infante, Shubham Pant, Johanna C. Bendell, William Charles Penley, Cassie M. Lane
Publikováno v:
Cancer Investigation. 33:477-482
Background: This phase I study determined the maximum tolerated dose (MTD) of AUY922 with capecitabine in advanced solid tumors. Methods: Capecitabine 1000mg/m2 PO BID was administered with escalating doses of AUY922 IV; the MTD of AUY922 was combine
Autor:
John Souglakos, Stylianos Kakolyris, Sophia Agelaki, Zacharenia Saridaki, Charalambos Kouroussis, Dimitrios Mavroudis, Vassilis Georgoulias, Nikolaos Vardakis, Nikolaos Androulakis, Lambos Vamvakas
Publikováno v:
Cancer Investigation. 23:505-510
To determine the dose-limiting toxicities (DLTs) and the maximum tolerated doses (MTD) of L-OHP plus 5-FU and LV in patients with advanced solid malignancies.Patients received escalated doses of L-OHP (starting dose 50 mg/m2) as a 2-hour IV infusion
Autor:
Karen Yocom, Alaknanda J. Preston, J.M. Michalski, Carl Friedman, Rachelle Lanciano, David M. Sherman
Publikováno v:
Cancer Investigation. 19:763-772
This multicenter, randomized, double-blind study compared the efficacy and safety of once-daily oral granisetron 2 mg (n = 134) and placebo (n = 126) as prophylaxis for nausea and emesis in patients receiving upper abdominal fractionated radiotherapy
Autor:
Claudia Leutner, Jürgen Remig, Axel Glasmacher, Günter Marklein, Tilman Sauerbruch, Marcus Gorschlüter, Ingo G.H. Schmidt-Wolf, C. Hahn
Publikováno v:
Cancer Investigation. 19:669-677
Abdominal infections are an important cause of morbidity and mortality in neutropenic patients. We present a retrospective series of 16 patients, mostly with acute leukemia, who developed severe abdominal infections during chemotherapy-induced neutro
Autor:
Laura Boldrini, Simona Nuti, Silvia Gisfredi, Gabriella Fontanini, Sabina Pistolesi, Giuliano Parenti, Silvia Ursino, Greta Alì, Nicola Pieracci, Katia De Ieso
Publikováno v:
Cancer investigation. 25(7)
COX-2 expression was evalueted in intracranial meningiomas, relating this molecule to grade, vasculature, VEGF and brain edema. Fifty-six tumors were evaluated for COX-2 and VEGF expression and for microvessel density. In 34/56 cases, the edema was e
Autor:
Eric Haltom, Neil Senzer, Donald Richards, Houston Duncan, John Nugent, Svetislava J. Vukelja, Barry Jones, Margaret J. Uprichard, Casey Cunningham, John Nemunaitis
Publikováno v:
Cancer investigation. 24(6)
PT-100 upregulates cytokine expression competitively inhibiting the dipeptidyl peptidase activity of fibroblast activation protein (FAP) and dipeptidyl peptidase IV (DPP-IV). This dose-escalation study was conducted to evaluate the safety of PT-100 i
Autor:
Rudolph M. Navari, Jake Vinson, Kenneth L. Kirsh, Cindy K Nagy, Steven D. Passik, Patrick J. Loehrer, Sin-Ho Jung
Publikováno v:
Cancer investigation. 22(3)
Chemotherapy-induced delayed emesis (DE) can affect up to 50% to 70% of patients receiving moderately and highly emetogenic chemotherapy, although rates are improving. DE most commonly occurs within the first 24 to 48 hours of chemotherapy administra
Autor:
Brian F. Issell, James A. Neidhart, John J. Rinehart, William C. Buhles, Evan M. Hersh, Pierre L. Triozzi
Publikováno v:
Cancer investigation. 15(5)
Recombinant human interleukin-1 beta (rhIL-1 beta) was evaluated in a phase 1 clinical trial in which patients with metastatic or unresectable solid tumors received carboplatin and etoposide in cycle 1 and carboplatin, etoposide, and rhIL-1 beta in c